Patent ID: 8349574
Filing Date: 2013-01-08
Classification: C07K,G01N

Abstract:
1. A method for determining whether a subject with a cancer is likely to respond to treatment with a Her family targeted agent, for predicting a time course of disease during treatment with a Her family targeted agent, and/or for predicting the probability of a significant event in the time course of the subject's cancer during treatment with a Her family targeted agent, comprising: (a) obtaining a biological sample from of the subject's cancer; (b) measuring the amount of Her-3 in the biological sample using a Her-3 antibody that specifically binds to a polypeptide sequence set forth in one of SEQ ID NOs 1-8; (c) determining whether the amount of Her-3 in the subject's sample is above a Her-3 cutoff; (d) correlating the amount of Her-3 measured in the biological sample to at least one of determining the relative likelihood of whether a subject with a Her-2 positive cancer will respond to treatment with a Her-family targeted agent, predicting a time course of disease during treatment with a Her family targeted agent, and/or predicting a probability of a significant event in the time course of the subject's cancer during treatment with a Her family targeted agent; and (e) indicating that the subject is more likely to respond to the Her family targeted agent, more likely to have a long time course during treatment with a Her family targeted agent, and/or less likely to have a significant event during treatment with a Her family targeted agent if the amount of Her-3 in the biological sample is below the Her-3 cutoff as compared to if the Her-3 in the biological sample is above the Her-3 cutoff.